Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Lucid Group Inc (LCID) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Lucid Group Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.88B), while Lucid Group Inc trades at $3.28 (market cap $1.32B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 6.7× Lucid Group Inc's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Lucid Group Inc for 45 Days on average.
| KYMR | LCID | |
|---|---|---|
Market Cap | $8.88B | $1.32B |
Volume | 1,028,790 | 8,737,624 |
Sector | Health | Consumer Cyclical |
52-Week High | $127.31 | $21.67 |
52-Week Low | $55.80 | $3.29 |
Typical Hold Time | 0 Days | 45 Days |
Enterprise Value | $8.27B | $4.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lucid Group (LCID) trades at $3.36, down 2.33% amid ongoing operational challenges. The stock shows bearish technical signals with all moving averages indicating selling pressure, though oversold RSI levels suggest potential near-term bounce. Fundamentally, the company continues to burn cash with negative gross margins of -96.56% and widening losses, while recent news highlights delayed product launches and aggressive cost-cutting initiatives targeting $1.4 billion in savings.
LCID faces significant headwinds with persistent losses and cash burn threatening viability, though strategic partnerships and cost reduction efforts provide some optimism. The stock trades at deep discounts to sales and book value, but requires successful execution on new vehicle launches and substantial margin improvement to justify analyst consensus price target of $7.00, representing 109% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →
